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Abstract: 
Current issues that are associated with the development of hepatitis B vaccine,  combination 
vaccines, modes of administration, immunogenicity, and efficacy of different types of hepati-
tis B vaccines are reviewed. Hepatitis B viral mutants can emerge as a result of either im-
mune response or treatment options. Several studies are in progress on treatment of chronic 
hepatitis B infection by immunization with multiple antigenic components; DNA vaccines 
alone or with DNA encoded immunomodulatory cytokines; combination of vaccine with antivi-
ral drugs and cytokines; and genetic manipulation of antigen presenting cells. Integrating 
hepatitis B vaccine doses into the global infant immunization program is not sufficient for 
hepatitis B virus (HBV) infection eradication. Implementing HBV schedule to high risk groups 
such as injection drug users, inmates of correctional centers, and persons at risk for sexually 
transmitted diseases, surveillance of hepatitis B infected subjects and refugees, access to 
immunization services and treatment is necessary. Further investigation is needed to assess 
factors that can impede an adequate antibody response, HBV variants, and the need for 
booster doses to preserve vaccine-induced immunity, vaccinating schedule for older children, 
evaluation of those vaccinated but in persistent contact in HBV-endemic areas. 
 










The prevalence of chronic hepatitis B vi-
rus infection varies by geographic region. 
Most of North America is a low-
prevalence (< 2%) area. Certain high-
prevalence pockets exist, especially areas 
with a high proportion of Asian immi-
grants and Alaskan and northern Cana-
dian Aboriginal populations, where rates 
of chronic HBV are as high as 5% to 
15%. In most low-prevalence areas, HBV 
infection is acquired mainly during ado-
lescence and mid-adulthood, whereas 
perinatal transmission is the main route 
in high-prevalence (> or = 8%) areas.(1) 
Worldwide, mothers are the driving force 
behind the infections that lead to hepato-
cellular carcinoma (HCC), because the 
HBV carrier state is inversely proportional 
to the age of the infant when infected.(2) 
Hepatitis B vaccines have been incorpo-
rated into national immunization pro-
grams in over 150 countries. The major 
humoral immune response is a common 
determinant of the surface antigen pro-
tein of the virus.(3) Approximately 5-10% 
of healthy immunocompetent subjects do 
not mount an antibody response (anti-
HBs). Non-response is associated with 
different HLA-DR alleles and impaired T 
helper (Th) cell response, among other 
factors such as route of injection, age, 
gender, and body mass. Studies are in 
progress on treatment of chronic hepati-
tis B infection by immunization with mul-
tiple antigenic components, combination 
of vaccine with antiviral drugs and cyto-
kines, T cell vaccines, DNA vaccines 
alone or with DNA encoded immuno-
modulatory cytokines, and direct genetic 
manipulation of antigen presenting 
cells.(3) Currently marketed HBV vaccines 
make use of DNA recombinant technol-
ogy by introducing the gene for HBsAg (S 
gene) into the genome of the yeast Sac-
charomyces cerevisiae. The two vaccines 
available are Recombinant HB and 
Engerix-B. The vaccines induce HBsAg-
specific helper T cells and T cell-
dependent B cells to produce neutralizing 
antibody against the "a" epitope (amino 
acid sequence 124-148) of HBsAg as 
early as 2 weeks after the first injec-
tion.(4, 5) 
A number of factors can impede an ade-
quate antibody response. Smoking, obe-
sity, injection into the buttock, chronic 
liver disease, presence of HLA-DR3, DR7, 
and DQ2 alleles, absence of the HLAA2 
allele, and extremes of age may be asso-
ciated with reduced immunogenicity. Re-
sponse rates also are lower in immuno-
compromised patients, such as transplant 
recipients, patients receiving chemother-
apy, and those with end-stage liver dis-
ease. Patients with chronic kidney dis-
ease should be vaccinated early in the 
course of their disease, before renal dis-
ease progresses, to ensure optimal re-
sponse to vaccination. The HBV vaccine 
is administered to all infants and children 
as a part of the universal immunization 
program. Adolescents who have not been 
vaccinated in infancy or childhood should 
also be vaccinated. In immunocompro-
mised patients and patients on dialysis, 
four vaccine doses are recommended.(6, 
7) 
In this manuscript the history, efficacy, 
immunogenicity, and long-term protec-
tion, mutants and HBV variants, new 
vaccines, combination of vaccines, com-
parison of two HBV vaccines and two HBV 
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vaccines administration, new adjutant, 
and vaccine safety will be reviewed. 
Methods: 
We performed a search conducted on 
hepatitis B vaccine immunity, efficacy, 
types, administration, and the impact of 
HBV vaccination on prevention of disease 
by using the electronic database MED-
LINE (1982 to 2009), EMBASE, OVID, 
Google (for Local websites and medical 
journals), and Websites of Iranian uni-
versities. 
History: 
The prevalence of hepatitis B surface an-
tigen and anti-hepatitis B core antibody 
in randomly selected 6583 subjects from 
three provinces in Tehran, Golestan, and 
Hormozgan of Iran was 2.6% and 
16.4%, respectively.(8) The seropreva-
lence of confirmed HBsAg was 0.6% in 
specimens of 1,004,889 volunteer blood 
donors in Tehran blood transfusion ser-
vice selected after interview and physical 
exam from 2003 to 2005 (9); 5% in sixty-
six subjects with confirmed diagnosis of 
hemophilia (10); 5.9% (CI 95%: 4.5–
7.3%) in 1113 Iranian large vehicle driv-
ers (11); 18% in 226 gypsies from Shahr-
e-Kord southwest of Iran (12) ; 10% in 
women and 14.2% in men who attended 
the laboratory for sexually transmitted 
diseases in the Northeast of Iran.(13) In 
Iran, Cuban hepatitis B vaccine became 
available approximately in 1994 and 
mass vaccination of neonates and chil-
dren was incorporated in the national 
vaccination scheme. In a study of 538 
children who received three doses of Cu-
ban hepatitis B vaccine: 15.6% were 
nonresponder (<10mIU/ml), 27.7% were 
hyporesponder (10-100mIU/ml), and 
56.7% were good responder 
(>100mIU/ml).(14) Children who had 
been immunized with Cuban recombinant 
hepatitis B vaccine and their antibody 
titers were <10mIU/ml (nonresponder) 
or10-100mIU/ml (hyporesponder), were 
administered booster dose of the same 
vaccine in the Deltoid muscle. The re-
sponse of 141 children with the mean 
age of 1.9 years to booster dose of vac-
cine was 94.3% and 100% vaccines with 
the first and second booster dose of vac-
cination, respectively.(15) Complete im-
munization coverage by age one year 
was better in rural areas than in urban 
areas. The reason for better coverage in 
rural areas was that village workers ac-
tively sought, visited and immunized 
children, while in urban areas physicians 
dominate care but do not often insist on 
immunization.(16) Among 339 health care 
workers vaccinated with three doses of 
HBV vaccine in Shiraz, Iran, anti-HBsAb 
titers was 10 - 100 mlU/mL in 25.1%, 
and <10 mlU/mL of 12.7% of subjects. 
Reassessment for revaccination in health 
care workers should be considered.(17) 
Mass campaign of immunization against 
hepatitis B registered for those born from 
1989 to March 2007 in Iran. During this 
campaign 1,320,000 people were vacci-
nated and about 90% coverage was 
reached. In order to extend the target 
groups for hepatitis B vaccination, the 
program recommended also vaccinating 
people with high risk occupations like 
firefighters and workers at city hall. It 
was concluded that 12% of the first tar-
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Universal infant hepatitis B immunization 
programs were initiated in Mongolia 
from1991. A survey was conducted in 
2004 on 593 children: the coverage of 
complete vaccination was 60.1%. A sig-
nificantly higher proportion of children in 
Metropolitan cities (75.2%) were com-
pletely vaccinated compared to those in 
Province centers (55.7%) and rural areas 
(59.1%). Only 17.0% of the children had 
protective anti-HBs which decreased from 
31.1% to 16.3% among 7 to 12-year-
olds indicating its decay with time.(19) 
Similarly, in Alaska and USA, the vaccine 
induced anti-HBs titer declined to 19% in 
the five years and 8% in the ten years of 
age.(20) The significant urban-rural differ-
ences in the prevalence of HBV infection 
and carriage suggest some potential gaps 
in the vaccination program implementa-
tion in remote areas. It should be noted 
that there was no significant differences 
in the risk of infection or in the frequency 
of HBV-infected mothers among urban 
and rural subjects.(21) One explanation 
may be improper vaccine storage and 
handling led to vaccine damage during 
the cold winter season in Mongolia. It is 
well known that HBV vaccine loses its 
immunological potency upon freezing or 
freeze drying.(22) According to a model-
based estimate, the annual number of 
HBV infections among 100,000 fully im-
munized children due to unsafe immuni-
zation injection was at least 135-3120. 
An insufficient supply of syringes, and 
the attitudes to justify reuse, were sig-
nificantly associated with the unsafe re-
use of a reusable syringe in most parts of 
the areas studied.(23) 
In Taiwan, a mass vaccination program 
for neonates born to HBsAg-positive 
mothers was launched in 1984, followed 
by immunization of all neonates in 
1986.(24) The average seroprevalence 
rate of hepatitis B surface antigen 
(HBsAg) in children aged less than 15 
years fell from 9.8% in 1984 to 0.7% in 
1999, with a similar-order drop in sero-
prevalence of anti-HBc from 20.6% to 
2.9%.(25) The difference of long-term ef-
ficacy between plasma-derived and re-
combinant hepatitis B virus vaccines and 
the effectiveness of catch-up vaccination 
in adolescents with undetectable anti-
HBs was investigated in Taiwan. Recom-
binant vaccine showed predominant dis-
appearance rate (62.7%) of anti-HBs 12-
15 years after vaccination, but provided 
better anamnestic response after a 
booster dose. It also showed high suc-
cess rate (97.3%) in catch-up vaccina-
tion in adolescents.(26) The prevalence of 
occult HBV infection among forty-six HBs 
Ag- negative HBV vaccinated children in 
Taiwan was 10.9% in at least two re-
gions, with mean titer 
1.60x10(4)copies/ml. Sequence analyses 
of S gene showed occult isolates were 
variants; no G145R but C139S vaccine 
escape mutant was found. Variation and 
deletion were found in pre-S region; pre-
S deletion was more frequent in 3' termi-
nus of pre-S1 which leads to loss of im-
mune epitopes and function sites.(27) 
In 6213 subjects aged 6 months to 60 
years from hospitals in Thailand, sero-
positive rates for HBsAg, anti-HBs, and 
anti-HBc was 4%, 41.6% and 26.5%, 
respectively. The HBsAg seropositive rate 
and anti-HBc was 0.7%, and 2.9% 
among children born after and 4.3%, and 
15.8% among children born prior to HBV 
vaccine integration into the expanded 
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program on immunization.(28) Of eighty-
seven high-risk individuals who had re-
ceived a complete course of recombinant 
HBV vaccine 18-20 years ago in Thailand, 
cellular immunity was determined by 
ELISPOT to detect HBV-specific IFN-
gamma-producing cells. Overall 58.6% 
were seroprotected (titer > or = 10 
mIU/mL). As for cellular immunity, 
50.6% were positive on ELISPOT. The 
majority of participants (81.8%) who 
were positive for IFN-gammaproducing 
cells were seropositive, but only 50% of 
seropositive participants were ELISPOT 
positive. Thus, 18-20 years after immu-
nization, it appears that a second booster 
dose should be considered, especially in 
high-risk groups.(29) In a study in inject-
ing drug users (IDUs) in Bangkok of 
Thailand, of the 189 HBV seronegative 
IDUs, 81.0% completed the vaccine se-
ries. IDUs with HIV had 6.5 time fold 
odds of vaccine non-response. These 
data underscore the need for, and feasi-
bility of, vaccine delivery in this popula-
tion and support targeting efforts at 
high-risk age groups.(30) Given the rela-
tively high prevalence of HBV infection 
(9.7%) of 371 HIV-infected patients, 
screening for HBV infection prior to ART 
initiation should not be omitted in the 
resource-limited setting.(31) 
Review of data of 1,485 HBsAg-positive 
pregnant in Alberta, Canada showed that 
of the 980 infants eligible to have com-
pleted prophylaxis and serological follow-
up, 82.0% were appropriately immunized 
and serologically tested. Of infants with 
complete immunization and follow-up, 
3.7% failed to mount an immune re-
sponse and 2.1% were infected. Future 
research should examine maternal fac-
tors that may increase the vertical 
transmission of HBV.(32) 
In the United States from 1990 to 2001, 
the overall incidence of acute hepatitis B 
declined by 66%, from 8.1 to 2.8 cases 
per 100,000. The decline was most dra-
matic among children 0–11 years old, 
with an 89% decline, from 1.1 to 0.12 
per 100,000.(33) Three-dose vaccination 
coverage for children aged 19–35 months 
increased from 16 percent in 1991 to 92 
percent in 2004.(34) There has also been 
progress towards full implementation of 
routine immunization of adolescents not 
previously vaccinated. Vaccination cover-
age among adolescents aged 13–15 
years increased from almost zero in 1993 
to 74 percent in 2004. The introduction 
of laws requiring immunization prior to 
school entry has been observed to coin-
cide with a rise in vaccination cover-
age.(35) Nearly all pregnant women in the 
United States receive prenatal HBsAg 
screening to identify those at risk of peri-
natal transmission to their infants.(36) On 
the basis of data from the 2004 National 
Health Interview Survey (37), hepatitis B 
vaccination coverage among all US adults 
(with and without indications for vaccina-
tion) is estimated to be 35 percent. The 
highest vaccination coverage rates 
among adults with an indication for vac-
cination have been observed among per-
sons with potential occupational exposure 
to HBV. Vaccination coverage among 
staff members at dialysis centers in the 
United States was 90 percent in 2002, 
well above the 56 percent coverage re-
ported among dialysis patients.(38) Data 
from the National Health Interview Sur-
vey showed that vaccination coverage 
among persons defined as "high-risk" for 
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sexually transmitted and blood borne 
diseases was only 30 percent in 2000 
and 45 percent in 2004.(39) Findings of 
other studies are also consistent with low 
vaccination coverage among adults at 
risk for disease. Among 1,755 men who 
have sex with men (MSM) visiting a 
sexually transmitted disease clinic in San 
Diego, California in 1998, 16 percent 
were vaccinated. Of 1106 persons report-
ing injection drug use at the same clinic, 
only 6 percent were vaccinated.(40) A 
study conducted in San Diego in 1997 to 
examine adherence to vaccination rec-
ommendations among adult household 
and sexual contacts of persons with 
chronic hepatitis B, found that only 13 
percent had received hepatitis B vac-
cine.(41) The prevalence for HBV in the 
United States has been estimated to be 
approximately 0.4%. However, these 
estimates have been based on surveys 
conducted in samples in which foreign-
born minorities were underrepresented. 
Voluntary screening data indicate preva-
lence in excess of 15% in some of these 
groups.(42) New HBV infections in the 
United States are becoming increasingly 
concentrated among populations such as 
injection drug users, inmates, and per-
sons at risk for sexually transmitted dis-
eases. Programs such as perinatal case 
management and venue-based vaccina-
tion of high-risk adults will need to be 
expanded and backed by a consistent 
commitment of resources.(43) 
Efficacy, immunogenicity and long-term 
protection 
The persistence of anti-HBs depends on 
the peak antibody level achieved after 
three doses.(44-47) Unresponsiveness to 
HBsAg has been attributed to a number 
of environmental and genetic factors. The 
most important are the haplotype of HLA 
antigens and immunological tolerance.(48) 
A variety of HLA classes I and II antigens 
have been reported to be associated with 
unresponsiveness to HBsAg in different 
ethnic populations.(49) Strong B-cell re-
sponses in acute and chronic infection 
mediate neutralization of HBV and reduce 
the spread of virus, thus giving protec-
tive immunity. The weak T-helper cell 
and cytotoxic Tlymphocyte responses in 
acute and chronic infection make for their 
limited role in immune control of viral 
replication and mean that core- and po-
lymerase-specific T-cell immunity is cru-
cial. Altogether, the conclusion is that 
HBV envelope antigens are suitable for 
use in protective vaccines or as adju-
vants for therapeutic vaccine but not for 
use in therapeutic vaccines per se.(50, 4) 
The third dose of vaccine in the infant 
immunization schedule produces a large 
and rapid rise in antibody such that it 
may be considered as itself a booster 
dose. By 10–15 years after the first im-
munization, anti-HBs titers have fallen to 
less than10 mIU/ml in some 10–50% of 
those vaccinated. Clearly, protection 
against clinically important disease out-
lasts the presence of detectable antibod-
ies. Revaccination after 10–13 years pro-
duced a response of >95%. The mecha-
nistic basis of immune memory is evi-
dently a complex interplay between 
memory B cells, memory T cells, memory 
cytotoxic T lymphocytes and antigen–
antibody complexes.(51- 52) In 2002, World 
Health Organization (WHO) repeated its 
view that booster doses of hepatitis B 
vaccine are not recommended for univer-
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sal hepatitis B immunization program.(53) 
Immunocompromised subjects should be 
regularly tested for anti-HBs titres and 
given a hepatitis B booster vaccination 
when the titer fall below10 mIU/ml.(54) 
Based on the currently available data 
there is no scientific evidence for giving 
booster doses of hepatitis B vaccine to 
fully immunized individuals. Although 
mutant hepatitis B viruses currently have 
little public health significance, regular 
monitoring is of importance to determine 
if vaccination fails to prevent infection by 
mutants. Should this occur, there might 
then be a need to revise immunization 
policies status.(55) Anti-HBs level in 
19.3% of 3752 children who were vacci-
nated in three cities of Iran was <10 
mIU/mL. The total geometric (GMT) 
mean titer was 34.5+/-0.66. Predictors 
were low birth weight and chronic dis-
ease.(56) A study evaluated the efficacy 
and immunogenicity of combined hepati-
tis B vaccination with plasma-derived 
vaccine (PDV) and recombinant vaccine 
(RV), and concluded four doses of vac-
cine are recommended in high-risk in-
fants when two types of vaccine are to be 
used in combination.(57) 
In a recent study, in vitro production of 
interleukin (IL)-2, interferon (IFN)-
gamma and IL-10 was investigated in 
Iranian healthy adults vaccinated with 
recombinant hepatitis B (rHB) vaccine. 
Peripheral blood mononuclear cells 
(PBMC) were isolated from 18 high re-
sponders and eight nonresponders and 
stimulated with rHB antigen or phyto-
haemaglutinin (PHA) mitogen. The re-
sults demonstrated a significant decrease 
in the production of IL-2, IFN-gamma 
and IL-10 in response to rHB antigen. 
The findings suggest that unresponsive-
ness to rHB vaccine may be owing to in-
adequate Th1- and Th2-like cytokine 
production.(58) 
A study was conducted to evaluate the 
influence of supplementary vaccination 
with a single low and standard dose of a 
recombinant hepatitis B (HB) vaccine in 
healthy Iranian non-responder neonates 
to primary vaccination. The results indi-
cate that a significant proportion of non-
responder neonates can be induced to 
develop a protective anti-HBs response 
following revaccination with a single low 
dose vaccine.(59) A 3-year follow-up study 
of long-term antibody persistence follow-
ing vaccination of low-risk preterm in-
fants with recombinant hepatitis B vac-
cine (HBV), showed that delaying vacci-
nation of premature infants against hepa-
titis B until a weight of 2,000 grams was 
reached, resulted in both a significantly 
higher percentage of children with posi-
tive antibody levels and a significantly 
higher geometric mean concentration 
(GMC) at 3-3.5 years of age as compared 
to early-vaccinated preterm infants.(60) 
Mutants, HBV variants 
Hepatitis B viral mutants can emerge in 
patients as a result of selection pressure 
from either immune response or treat-
ment options. Mutations that occur within 
the immunodominant epitopes of hepati-
tis B surface antigen (HBsAg) allow mu-
tant virus to propagate in the presence of 
a neutralizing immune response, while 
wild-type virus is reduced to undetect-
able levels. An understanding of immu-
noassay reactivity with HBsAg mutants is 
key to establishing an appropriate testing 
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algorithm for hepatitis B virus detection 
programs.(61) 
More than 20 years have elapsed since 
1984, when vaccination against Hepatitis 
B began, first with a plasma-derived vac-
cine and later a recombinant DNA-
derived vaccine. The appearance of 
Hepatitis B surface gene mutants in DNA 
HBV positive children has been con-
firmed, gradually increasing from 7.8% 
before vaccination to 23.1% 15 years 
later. To date, there is no evidence that 
those viruses are disrupting the efforts to 
control Hepatitis B through immunization 
programs.(62)  
Numerous mutant hepatitis B viruses 
have been identified, with various muta-
tions having been detected in almost 
every part of the viral genome.(63) Some 
nucleotide changes allow the virus to es-
cape the effects of vaccination and 
treatment. There have been reports of 
infants born to HBeAg positive mothers 
who developed breakthrough infections 
despite having undergone full passive–
active immunoprophylaxis. Some of 
these instances have been attributed to 
strains of HBV with mutations in the an-
tigenic determinant of HBsAg that result 
in weak binding to anti-HBs.(64-65). A 
study in vaccinated children in Singapore 
(66-67) showed that the antigen and anti-
body can coexist, and that mutants per-
sisted for at least 13 years. Existing evi-
dence suggests that HBsAg mutants may 
cause persistent infection and be associ-
ated with chronic hepatitis. They may 
also hinder detection of HBsAg in HBV 
infection. Mutants can infect unvacci-
nated subjects but whether they can in-
fect vaccinated people is unclear. WHO 
recommends the establishment of an in-
dependent global network for appropriate 
monitoring of such vaccine/ treatment-
escape mutants.(68-69) Vaccine failures 
due to HBV variants with mutations in 
the small surface protein (S) gene (S 
mutants) have occurred in perinatally 
exposed infants who received hepatitis B 
vaccine or hepatitis B immune globulin 
appropriately and who have concentra-
tions of anti-HBs that are usually protec-
tive.(70) There has been concern that 
these HBV variants, which are sometimes 
resistant to the neutralizing effect of anti-
HBs, could threaten the effectiveness of a 
hepatitis B immunization programs and 
that immunization may accelerate the 
formation of HBV variants.(71) 
A study using sensitive detection meth-
ods demonstrated that the S mutants 
implicated in perinatally exposed infant 
vaccine failures were usually of maternal 
origin and not induced by vaccination.(72) 
In addition, mothers of infants who re-
sponded to vaccination were as likely to 
have these surface antigen variants as 
mothers of infants who did not respond, 
suggesting that infections among vacci-
nated children with S mutants repre-
sented immunoprophylaxis failures and 
infection with maternal viral variants 
rather than breakthrough infections 
among successfully vaccinated infants.(73) 
Most commercially available assays that 
employ polyclonal anti-HBs detect S mu-
tants, making ongoing surveillance for S 
mutants possible.(74) Introduction of ad-
ditional nucleoside/nucleotide analog 
agents for hepatitis B treatment will 
likely lead to the development of further 
unique polymerase mutants with varying 
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pathogenicity and cross-resistance to 
existing drugs.(75) 
New vaccines, combination of vaccines 
Genetically engineered subunit vaccines 
are more costly to manufacture than 
conventional vaccines, since the antigen 
must be purified to a higher standard 
than was demanded of older, conven-
tional vaccines. Recombinant subunit 
vaccines have a tendency to be less im-
munogenic than their conventional coun-
terparts.(76) A study discussed the new 
field of application of antigen-pulsed 
dendritic cells (DCs) for prophylactic pur-
poses when adequate levels of protective 
antibody cannot be induced by traditional 
vaccination approaches.(77) 
Combined hepatitis A and B vaccine, 
(Twinrix, GlaxoSmithKline Biologicals) is 
safe, well-tolerated and has demon-
strated a highly immunogenic profile. 
Persistence of anti-HAV and anti-HBs an-
tibodies in adults remains high for at 
least 10 years after primary vaccina-
tion.(78) All available data on monovalent 
and combined hepatitis A and hepatitis B 
vaccines indicates that there is no sup-
port for a hepatitis A or hepatitis B 
booster when a complete primary vacci-
nation course is offered to immunocom-
petent individuals.(79) 
Plasma-derived vaccines and yeast-
derived recombinant vaccines against 
HBV infection have gained an acceptable 
record of efficacy. However, non- or hy-
poresponsiveness to immunization does 
not only occur in cases of obesity, renal 
failure or immune suppression, but also 
in healthy individuals. There is a rationale 
for developing more immunogenic vac-
cines against HBV, especially for those 
populations who are potential non- or 
hyporesponders. Currently used recom-
binant hepatitis B vaccines consist of an-
tigen particles assembled with the prod-
uct of 226 amino acids encoded in the S 
gene. Since proteins encoded in the pre-
S gene are also incorporated in the HBV 
envelope, pre-S gene products should, at 
least in theory, be useful in improving 
protection with hepatitis B vaccines. In-
activated hepatitis A vaccines are more 
potent than currently used hepatitis B 
vaccines. Two injections of a standard 
dose of HAVRIX (SB) by the intramuscu-
lar route, or even a single injection using 
a higher dose (HAVRIX 1440), will 
achieve protective levels of antibodies. 
New hepatitis A vaccines are likely to be 
recombinant or attenuated live types.(80) 
A Study on 126 healthy 2-month-old in-
fants that were given a bivalent Haemo-
philus influenzae type bhepatitis B vac-
cine (bivalent Hib-HB vaccine; COMVAX) 
concurrently with priming doses of diph-
theria-tetanus-pertussis vaccine (DTP), a 
booster dose of diphtheria-tetanus-
acellular pertussis vaccine (DTaP), inacti-
vated or oral polio vaccine (IPV or OPV) 
and measles-mumps-rubella vaccine (M-
M-R(II)) confirmed that they have satis-
factory antibody responses to all anti-
gens. Concurrent administration of biva-
lent Hib-HB vaccine with priming doses of 
DTP, a booster dose of DTaP, OPV, IPV, 
or M-M-R (II) was well tolerated and, 
with the possible exception of rubella, did 
not substantially impair the antibody re-
sponse to any antigen.(81) In a study, 
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inactivated poliovirus-Haemophilus influ-
enzae b conjugate-hepatitis B virus 
(DTaP-IPV-Hib-HBV) vaccine in 708 in-
fants immunized at 2, 3, 4, and 12-14 
months of age was compared. All vaccine 
formulations were well tolerated. The 
three PRP-OMPC formulations met pre-
specified immunogenicity criteria, and 
the one with the lowest PRP-OMPC con-
centration was selected for further opti-
mization of immunogenicity.(82) 
Compare of two HBV vaccines 
A study compared two recombinant 
hepatitis B vaccines. One hundred sev-
enty-three infants meeting eligibility cri-
teria were given either GeneVac-B (Se-
rum Institute of India Ltd.) or Engerix-B 
(GlaxoSmithKline Beecham) in a random 
fashion. The seroprotection rates were 
similar for both vaccines (96% and 95%, 
respectively). The study concluded that 
GeneVac-B is as immunogenic and as 
well tolerated as Engerix-B when admin-
istered with DTPw vaccine at 6, 10, and 
14 weeks of age.(83) 
Compare of two HBV vaccines administra-
tion 
To compare the efficacy of low-dose in-
tradermal HBV recombinant vaccine with 
standard intramuscular dose in neonates, 
165 apparently healthy neonates born in 
Shiraz, Iran were randomized to receive 
either recombinant (corrected dosage) 
vaccine intramuscularly or intradermally. 
Intradermal vaccination with 20% of 
standard dose is as effective as intra-
muscular vaccination when evaluated at 
18 months after the first dose.(84) One to 
10 per cent of healthy adult individuals 
do not produce protective levels of anti-
HBs antibodies, following a standard vac-
cination protocol. Lack of a HBs antigen 
(Ag)-specific T-cell repertoire is amongst 
the possible defects, which may lead to 
humoral unresponsiveness and is the 
main objective of this study. We analyzed 
TcR BV (T-cell receptor beta chain vari-
able) gene usage in T lymphocytes from 
nine healthy adult responders and six 
nonresponders to recombinant HB vac-
cine, before and after booster vaccina-
tion. When the usage of each TcR BV 
gene within CD4+ and CD8+ T cells of 
the responders was compared with that 
of nonresponders, statistically significant 
difference was noted for BV5S2-3 gene 
family in CD4+ T cells of nonresponders. 
The results show that T-cell response to 
HBsAg is generally oligoclonal and in-
volves multiple BV families. Furthermore, 
overexpressed individual TcR BV genes 
and CDR3 length distributions in re-
sponse to HBsAg are subject-
dependent.(85) 
A study concluded that the underlying 
causes of poor anti-HBs response in 
HBsAg carrier children who had cleared 
HBsAg but failed to develop anti-HBs af-
ter receiving three doses of HB vaccine, 
and subsequent one dose of the same 
vaccine, are multifactorial including spe-
cific failure of antigen presentation or T-
cell activation, or the lack of T helper 
(Th)2 cell-like response to HBsAg. 
HLADRw14-DRw52 does not confer abso-
lute nonresponsiveness to HBsAg.(86) 
In a randomized trail using a recombi-
nant vaccine (Heberbiovac) to compare 
immunogenecity and safety of an in-
tradermal low-dose (4 microg) with stan-
dard dose (20 microg) of intramuscular 
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vaccination in healthy Iranian population, 
the overall seroprotection rate (anti-HBs 
level > or = 10 IU/L) was 97.3% for in-
tradermal vaccination group, which was 
not different from that of intramuscular 
vaccination group (98.55%). GMT of 
anti-HBs was not significantly different-
between the two groups.(87) 
New adjuvant 
There have been promising develop-
ments in the area of new adjuvant and 
delivery systems. The practical need for 
reducing the total number of childhood 
vaccinations has driven development of, 
multivalent and combination vaccine 
formulations. Efforts have been made in 
the critical area of therapeutic application 
of the vaccine.(88) 
A study evaluated the ligands for Toll-like 
receptor 7 (TLR7) (R-848) and TLR 9 
(CpG ODN) as adjuvants to augment the 
cellular and humoral immune responses 
as well as the generation of long-lasting 
immune memories following the vaccina-
tion with HBsAg in mice. The immune 
responses were assessed by enzyme-
linked immunosorbent assay (ELISA), 
enzyme-linked immunospot (ELISPOT), 
and fluorescence-activated cell sorter 
(FACS) at the total and single-cell levels. 
The results imply that CpG ODN and R-
848 may be the candidates as adjuvants 
for use in prophylactic and therapeutic 
hepatitis B vaccine.(89) The efficacy of 
granulocyte macrophage colony-
stimulating factor (GM-CSF) to enhance 
the immune response to hepatitis B virus 
vaccine has been the subject of several 
reports. According to a study, GM-CSF 
induced a significant effect in terms of 
response rate and achievement of an 
earlier seroconversion to the vaccine in 
the overall populations examined (renal 
failure patients and in healthy individu-
als).(90) 
CPG 7909 is an oligodeoxynucleotide 
containing immunostimulatory CpG mo-
tifs that activate human B and plasmacy-
toid dendritic cells via Toll-like receptor 
9. The immunostimulatory properties of 
CPG 7909 present an important strategy 
in achieving longterm protection in HIV-
infected patients and other HBV vaccine-
hyporesponsive populations.(91) 
Vaccine safety 
At present, there are no data to conclude 
that hepatitis B vaccines pose a serious 
health risk or justify a change in current 
immunization practice. However, vaccine 
"scares" continues to have an interna-
tional impact on immunization coverage. 
Creating a positive environment for im-
munization can be achieved by reposi-
tioning the value of vaccines and vacci-
nation, supported by evidence-based in-
formation. The role of international or-
ganizations, the media, and the industry 
in the implementation of communication 
strategies was discussed and the impact 
of litigation issues on vaccinations were 
evaluated. The Viral Hepatitis Prevention 
Board confirms its commitment to cur-
rent recommendations for universal and 
risk group hepatitis B vaccination and 
further encourages the conduct of vac-
cine safety studies and the dissemination 
of their results.(92) Lichen planus is a pru-
ritic inflammatory dermatosis of unknown 
origin. An increased prevalence of a wide 
range of liver disease in lichen planus has 
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been observed by many authors. Most 
recently, many reports observed the oc-
currence of lichen planus after admini-
stration of different types of hepatitis B 
vaccines.(93) 
In conclusion: 
Intensifying HB vaccination of high risk 
groups, surveillance of hepatitis B in-
fected subjects, and control on the health 
status of refugees will further decrease 
the frequency of the disease. In addition 
the consideration of all possible routes of 
transmission in subjects without risk fac-
tors for infection is necessary.(94) Advi-
sory Committee on Immunization Prac-
tices (ACIP) recommends universal hepa-
titis B vaccination for all unvaccinated 
adults. In other primary care and spe-
cialty medical settings in which adults at 
risk for HBV infection receive care, 
health-care providers should inform all 
patients about the health benefits of vac-
cination, including risks for HBV infection 
and persons for whom vaccination is rec-
ommended, and vaccinate adults who 
report risks for HBV infection and any 
adults requesting protection from HBV 
infection.(95) Causes of vaccine failure 
and HBV variants need to be assessed. 
To eliminate HBV transmission, global 
infant immunization programs and spe-
cific populations at high risk for HBV ex-
posure have to be made. Access to set-
tings for health seeking behavior and 
preventive care and immunization ser-
vices and treatment are necessary for 
populations mentioned below: 
-Persons at risk for sexual transmission, 
sex partners of persons who are positive 
for hepatitis B surface antigen (HBsAg), 
persons evaluated or treated for sexually 
transmitted diseases, including human 
immunodeficiency virus infection, men 
who have sex with men 
- Persons at risk for transmission by per-
cutaneous or mucosal exposure to blood 
- Household contacts of HBsAg-positive 
persons 
-Current or recent injection drug users, 
including needle-sharing contacts of 
HBsAg-positive persons 
-Health care and public safety workers 
with a reasonably anticipated risk of ex-
posure to blood or blood-contaminated 
body fluids 
-Persons with end-stage renal disease, 
including predialysis, hemodialysis, peri-
toneal dialysis, and home dialysis pa-
tients 
- International travelers to areas with 
high or intermediate levels of endemic 
hepatitis B virus infection (HBsAg preva-
lence 2%) 
-Persons with chronic liver disease 
-Correctional facilities 
-All persons seeking protection from 
hepatitis B virus infection 
HLA= Human Leukocyte antigens 
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